SkipNav
Quality Measures
YNHH

Quality Measures

Outcomes Reporting

Patients face an increasingly complex decision when deciding where to go for their cancer treatment. There are several factors that can aid in that decision-making process including location, center designation, physician experience, physician referral, health plan coverage, and options for treatment. In addition to these factors, nationally accepted quality measures, outcome data, and patient satisfaction information can also be helpful tools in comparisons between cancer treatment centers or hospitals.

ACSO/NCCN Quality Measures

Smilow Cancer Hospital at Yale-New Haven and Yale Cancer Center acknowledge the seven American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) evidence-based quality guidelines for breast and colorectal cancers. The latest performance data for the Breast Cancer Program and Gastrointestinal Cancers Program in the treatment of these diseases is listed below.

Colorectal Cancer Performance Rates

Performance Measure 4 5 6 7 8
Adjuvant Chemotherapy (C/CT)1 80% 88% 73% 88% %
12 Regional Lymph Nodes
(C/12RLN)2
89% 88% 90% 91% 95%
Adjuvant Radiation Therapy (R/RT)3 % 80% 83% % %
Postoperative Adjuvant Chemotherapy Therapy (R/CT)4 - - 50% 89% 88%
  1. Adjuvant chemotherapy is considered or administered within 4 months of diagnosis for patients under the age of 80 with stage III (lymph node positive) colon cancer.
  2. At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.
  3. Radiation therapy is considered or administered within 6 months of diagnosis for patients under the age of 80 with clinical or pathologic T4N1M0 or stage III colorectal cancer after receiving surgical resection for rectal cancer.
  4. Postoperative adjuvant chemotherapy is administered within 9 months (270 days) of diagnosis to patients under the age of 80 with clinical or pathologic AJCC Stage II or Stage III receiving surgical resection for rectal cancer.

NMDP Allogeneic Bone Marrow Transplant Center Data

The National Marrow Donor Program tracks data on patients who have received a transplant at accredited United States Transplant Centers. Yale Cancer Center's actual results are above the predicted survival range. The following chart shows how Yale Cancer Center compares to Transplant Centers in the United States reporting more than 50 allogeneic transplants during the most recent reporting period (2010 – 2012):

Transplant Centers Comparison Chart

Institution # of Patients One-Year Survival Predicted Survival
Yale University/Yale-New Haven Hospital 126 71.3% 60.4%
B 442 76% 65.9%
C 769 74.6% 63.9%
D 63 74.6% 66.6%
E 762 73.8% 64.6%
F 284 73.6% 61.5%
G 83 73.2% 66.5%
H 414 73% 62.6%
I 253 73% 62.6%
J 435 71.9% 67.5%
K 494 71.7% 60.8%
L 213 70% 60.7%
M 117 70% 64.7%
N 193 69.8% 58.5%
O 159 67.3% 52.2%
P 701 67% 60.6%
Q 334 65.5% 58.9%
R 214 65.4% 63.6%
S 468 65.3% 61.1%
T 130 63.4% 56.4%
U 84 63.1% 62%
V 285 63.2% 58.5%
W 73 63% 49.2%
X 1098 62.7% 59.2%
Y 326 62.6% 55.3%
Z 64 62.5% 51.7%
AA 124 62.1% 58.4%
BB 145 62% 60.6%
CC 178 61.7% 58.3%
DD 151 61.6% 57.9%
EE 230 61.2% 60%
FF 309 61.1% 50.1%
GG 93 60.2% 53.8%
HH 112 59.8% 60.2%
II 156 59.5% 49.7%
JJ 229 59.4% 57.1%
KK 141 59.4% 56.7%
LL 180 59.2% 61.9%
MM 144 58.3% 51.6%
NN 95 57.8% 46%
OO 217 57.3% 58.9%
PP 65 56.9% 53%
QQ 152 56.2% 51.5%
RR 224 56.1% 53.7%
SS 73 55.5% 52.2%
TT 163 54.9% 48.5%
UU 224 54.6% 55.2%
VV 159 53.2% 52%
WW 338 52.6% 50.4%
XX 437 52.4% 51.9%
YY 96 54% 52%

*based on overall disease condition of treated patients, measured on a scale from 1 (low risk) to 5 (high risk).

Our Physicians

Use our online tool to find a doctor

Yale Cancer Center
Magnet Recognition Best Hospitals 2012-2013
Visit Closer to Free